AI illustration · not actual product photoDetails from the source.
Source-listed IGF-1LR3 (SKU IG01): 0.1mg*10vials. PriceList(1).pdf lists 41 per 10 vials but does not specify currency; the website displays $41 per 10 vials in USD per owner instruction. The source row does not establish the supplier-specific item's identity, lot quality, or approval.
- Catalogue code
- IG01
- Source specification
- 0.1mg*10vials
- Source document
- PriceList(1).pdf, page 3
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
IGF-1LR3 is a catalog label commonly associated in scientific literature with Long R3 IGF-I, an engineered IGF-I peptide/protein analogue. The catalog does not establish that either supplied vial actually contains that exact analogue, nor identify its manufacturer, sequence, purity, formulation or regulatory pathway. Do not describe the catalogued vial as FDA-approved, compounded or research-only without product-specific evidence.
Biological mechanism
Native IGF-I binds IGF-1 receptors and activates intracellular growth and survival signaling, including PI3K/Akt and MAPK pathways. The Long R3 analogue is described as having an arginine substitution at position 3 plus a 13-amino-acid N-terminal extension; these changes are reported to reduce its binding to IGF-binding proteins, which normally regulate IGF availability. This mechanism describes the named analogue in research literature, not a confirmed composition of these vials. [3] [4]
Research focus
Experimental research on IGF signaling and cellular growth/metabolic processes, including cell-culture work that used LR3-IGF-I in cultured mouse adipocytes to examine glucose uptake. Laboratory or cell-model findings do not show clinical benefit in people. [3] [4]
Potential applications in the evidence
The evidence reviewed supports only describing laboratory investigation of IGF signaling and growth- or metabolism-related cellular processes. No clinical application for IGF-1LR3 is established by the sources reviewed. [3] [4]
Human evidence
I did not identify controlled human efficacy or safety studies of Long R3 IGF-I in the sources reviewed. A ClinicalTrials.gov search for the exact term “IGF-1 LR3” returned no records; that exact-term search does not prove no human research exists anywhere. Human studies and FDA-approved use of mecasermin concern a distinct product/formulation and cannot establish efficacy or safety for LR3 or this catalogued vial. A published analytical case report found Long R3 IGF-I, including a His-tagged form, in an unlabelled injection vial; it was not a treatment study and noted that effects of the tagged protein in humans had not been elucidated. [1] [2] [5] [6]
Known and potential effects
Adequate human safety data for IGF-1LR3 were not identified, so its human adverse-effect frequency and severity are unknown. As a cautious pharmacological comparison only, the FDA mecasermin label reports severe hypoglycemia, hypersensitivity including anaphylaxis, and tonsillar hypertrophy among clinical-trial adverse reactions, and warns about intracranial hypertension, slipped capital femoral epiphysis, scoliosis progression and malignant neoplasia. These are not established LR3-specific effects. [1] [3]
Safety and contraindications
The FDA mecasermin label contraindicates that approved product in specified circumstances, including hypersensitivity, closed epiphyses and malignant neoplasia. These are not verified contraindications for the catalogued IGF-1LR3 vial; avoid transferring mecasermin labeling as though the products were identical. Without batch-specific identity, purity, formulation and sterility information, risks for the exact vial cannot be verified. IGF growth signaling and the limited direct LR3 human evidence warrant a conservative description; no safety guarantee can be made. [1] [3] [6]
U.S. FDA / regulatory status
FDA’s Drugs@FDA record lists INCRELEX (recombinant mecasermin), injection, for subcutaneous use, and its prescribing information specifies a pediatric indication and restrictions. This is not approval of the modified IGF-1LR3 analogue, and approval does not transfer to this supplier-specific vial. No FDA approval for IGF-1LR3 was identified in the FDA sources reviewed. The supplied catalog does not identify the vial’s manufacturer, lot, formulation source, jurisdiction or approval/application number, so its exact U.S. regulatory status cannot be verified. Do not call it compounded or research-only without reliable product-specific documentation. [1] [2]
Evidence limitations
Direct LR3 evidence cited here is largely mechanistic or cell-based. Animal, cell-culture, native IGF-I and mecasermin findings cannot establish efficacy, safety, identity, purity, sterility, formulation or intended regulatory status for the listed product. The product label alone does not authenticate vial contents. The catalog PDF lists source SKU IG01 as *10vials at 41, and SKU IG1 as *10vials at 180; the currency is not stated. Preserve the exact listing label IGF-1LR3. [1] [3] [4] [5] [6]
Supporting sources
- INCRELEX mecasermin Prescribing Information U.S. Food and Drug Administration · Official prescribing label. Supports: FDA-approved mecasermin indication, product-specific contraindications, warnings and adverse reactions; comparison only, not evidence for LR3.
- Drugs@FDA BLA 021839 INCRELEX U.S. Food and Drug Administration · Official FDA drug database. Supports: Identifies the FDA-listed product as INCRELEX, active ingredient recombinant mecasermin, its strength and dosage form; distinguishes it from IGF-1LR3.
- Insulin-Like Growth Factor-1 and Its Monitoring in Medical Diagnostic and in Sports Biomolecules / PubMed Central · Peer-reviewed review. Supports: IGF-I biology, IGF receptor signaling, IGF binding proteins, Long R3 IGF-I structural changes and reduced binding to IGFBPs; contextual safety discussion.
- Insulin-Like Growth Factor Binding Protein-2 Independently of IGF-1 Induces GLUT-4 Translocation and Glucose Uptake in 3T3-L1 Adipocytes Oxidative Medicine and Cellular Longevity / PubMed Central · Peer-reviewed primary in-vitro study. Supports: Long R3 analogue description and its use in a cultured mouse adipocyte study; supports experimental-cell evidence, not human therapeutic outcomes.
- ClinicalTrials.gov search for IGF-1 LR3 U.S. National Library of Medicine, NIH · Government clinical-trial registry search. Supports: The exact-term registry search returned no records at review; supports a qualified statement about registry search results, not a universal absence claim.
- Detection of His-tagged Long-R3-IGF-I in a black market product Growth Hormone & IGF Research / Elsevier · Peer-reviewed analytical case report. Supports: Analytical identification of Long R3 IGF-I and a His-tagged form in an unlabelled vial; highlights product-identity uncertainty and that the report was not a human treatment study.